pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

2026 Nobel Prize awarded to U.S. and German scientists for optogenetics breakthroughs

Oct 5, 2026·read at STAT ↗Neutral

The 2026 Nobel Prize in Physiology or Medicine was awarded to three researchers for their pioneering work on optogenetics.

The laureates-Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute, Peter Hegemann of Humboldt University in Berlin, and Georg Nagel of the University of Würzburg-developed methods that combine light with genetic modifications to switch individual neurons on or off in living brains.

This technology lets scientists precisely control specific brain cells, providing new insights into how neural circuits shape memory, emotion and behavior, and it could influence future neuroscience research and therapeutic strategies.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Could we one day vaccinate against every cancer?”

read at STAT ↗
1,149 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Stanford University2Moderna, Inc.PATH
drugs
BRIXADIBUTRANSSUBLOCADEbuprenorphinebuprenorphine ERcaffeine
topics
Oncology5Vaccines5Approval2Vaccine2CardiologyImmunologyMelanomaPeptide TherapeuticmRNA TherapeuticmRNA Vaccine

related stories

  • 3d agoFoghorn cuts 40% of workforceBioSpace
  • Sep 145 drugmakers chasing Merck and Moderna in the cancer vaccine raceBioSpace
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Aug 6Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive